Selected article for: "chronic HCV infection and hepatitis serum"
Author: Toma, Letitia; Dodot, Mihai; Zgura, Anca; Bacalbasa, Nicolae; Silaghi, Andrei; Simu, Razvan; Isac, Teodora; Mercan-Stanciu, Adriana
Title: Calprotectin in viral systemic infections—COVID-19 versus hepatitis C virus
  • Cord-id: ql6vuoe1
  • Document date: 2021_7_12
    • ID: ql6vuoe1
    Snippet: This study aims to evaluate differences in serum and fecal calprotectin in patients with HCV chronic hepatitis and COVID-19 infection and compare them to a control group. This observational study was performed between April 2020 and October 2020 in a single Internal Medicine center. We determined serum and fecal calprotectin, as well as levels of transaminases, C-reactive protein, ferritin, in 25 patients with COVID-19 infection, 30 patients with active HCV chronic infection and 38 patients with
    Document: This study aims to evaluate differences in serum and fecal calprotectin in patients with HCV chronic hepatitis and COVID-19 infection and compare them to a control group. This observational study was performed between April 2020 and October 2020 in a single Internal Medicine center. We determined serum and fecal calprotectin, as well as levels of transaminases, C-reactive protein, ferritin, in 25 patients with COVID-19 infection, 30 patients with active HCV chronic infection and 38 patients with cured HCV infection. Serum levels of ALT, AST, C-reactive protein and ferritin were significantly higher in patients with COVID-19 infection (mean values of 127 IU/mL, 135 IU/mL, 123 mg/L and 1034 ng/mL, respectively) than in patients with active HCV infection (mean values of 68 IU/mL, 51 IU/mL, 17 mg/L and 528 ng/mL, respectively) or in patients with cured HCV infection (37 IU/mL, 29 IU/mL, 3.4 mg/L and 274 ng/mL, respectively). Also, serum and fecal calprotectin had increased concentrations in patients with COVID-19 (7.3 µg/mL and 394 µg/mg) versus patients with active hepatitis (2.4 µg/mL and 217 µg/mg) and patients with cured hepatitis (1.2 µg/mL and 38 µg/mg). Values were significantly higher in patients with digestive symptoms related to COVID-19. Serum and fecal calprotectin can be used as inflammatory markers in patients with active viral infections. In COVID-19, calprotectin concentrations can be correlated to the severity of disease, particularly in patients with digestive symptoms.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and liver damage: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and liver disease stage: 1
    • abdominal pain nausea and active infection: 1
    • abdominal pain nausea and liver damage: 1, 2, 3, 4, 5, 6, 7
    • abdominal pain nausea and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • abdominal pain nausea diarrhea and active infection: 1
    • abdominal pain nausea diarrhea and liver damage: 1, 2, 3, 4
    • abdominal pain nausea diarrhea and liver disease: 1, 2, 3, 4, 5, 6
    • active infection and liver damage: 1, 2
    • active infection and liver disease: 1, 2, 3, 4, 5
    • active infection and liver disease stage: 1
    • active infection patient and liver damage: 1
    • active infection patient and liver disease: 1